Addition of binimetinib after refractory to encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2614541
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Encorafenib 300 mg once daily
Binimetinib 45 mg twice daily
Cetuximab 400 mg/m^2 Day 1, 250 mg/m^2 Day 8, 15, 22 (250 mg/m^2 from Cycle 2 later)
These treatments are repeated every 28 days in one cycle.
Primary outcome(s): Progression-free survival rate at 12 weeks after first protocol treatment
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
创建时间：
2022-02-15
